Stem-cell transplantation in multiple myeloma: how far have we come?

94 An exploratory landmark performed achieved [median interval from randomization to HDT/Rd cycle 5: 117/122 days; n = 103(B)/114(A)] showed a trend toward superior PFS (23.3 versus 20.1 months; HR 0.74; p = 0.09) and significantly superior OS (not reached versus 57 months; HR 0.56; p = 0.046) in arm B versus A. 94 A subgroup analysis evaluating the benefit of PFS, OS, or both from ASCT showed improved outcomes in patients with front-line ASCT and patients with low risk according to Lactate Dehydrogenase (LDH), cytogenetics, and R-ISS. 95 Allogeneic stem-cell transplantation Studies have shown conflicting results regarding the benefit of allo-SCT in MM.

also in 53,322 other papers

24 In addition, the bortezomib arm achieved better results in patients with t(4;14), although it did not reach statistical significance. 24 The long-term results published in 2018 showed similar results. 89 Bortezomib use was associated with improved outcomes in renal impairment and the effect of del(17p13) was abrogated in the bortezomib arm. 89 With regard to t(4;14), similarly, patients with the bortezomib arm showed improved OS

also in 111,027 other papers